Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4090734
Max Phase: Preclinical
Molecular Formula: C35H40N5NaO8
Molecular Weight: 659.74
Molecule Type: Small molecule
Associated Items:
ID: ALA4090734
Max Phase: Preclinical
Molecular Formula: C35H40N5NaO8
Molecular Weight: 659.74
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CNCc2ccccc2)O[C@@](OCCCn2cc(-c3ccc(-c4ccccc4)cc3)nn2)(C(=O)[O-])C[C@@H]1O.[Na+]
Standard InChI: InChI=1S/C35H41N5O8.Na/c1-23(41)37-31-29(42)19-35(34(45)46,48-33(31)32(44)30(43)21-36-20-24-9-4-2-5-10-24)47-18-8-17-40-22-28(38-39-40)27-15-13-26(14-16-27)25-11-6-3-7-12-25;/h2-7,9-16,22,29-33,36,42-44H,8,17-21H2,1H3,(H,37,41)(H,45,46);/q;+1/p-1/t29-,30+,31+,32+,33+,35+;/m0./s1
Standard InChI Key: HUQSIIXESMMRMR-NHWAYZLVSA-M
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 659.74 | Molecular Weight (Monoisotopic): 659.2955 | AlogP: 1.97 | #Rotatable Bonds: 15 |
Polar Surface Area: 188.29 | Molecular Species: ZWITTERION | HBA: 11 | HBD: 6 |
#RO5 Violations: 3 | HBA (Lipinski): 13 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.20 | CX Basic pKa: 8.60 | CX LogP: 0.25 | CX LogD: 0.22 |
Aromatic Rings: 4 | Heavy Atoms: 48 | QED Weighted: 0.10 | Np Likeness Score: -0.22 |
1. Prescher H, Frank M, Gütgemann S, Kuhfeldt E, Schweizer A, Nitschke L, Watzl C, Brossmer R.. (2017) Design, Synthesis, and Biological Evaluation of Small, High-Affinity Siglec-7 Ligands: Toward Novel Inhibitors of Cancer Immune Evasion., 60 (3): [PMID:28103033] [10.1021/acs.jmedchem.6b01111] |
Source(1):